Indication: Prostate Cancer

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant

Sub-indication: Patients treated with docetaxel in the mHSPC are eligible

Line of Therapy: 1st line in metastatic setting

Drug Study

Principal Investigator: Arash Rezazadeh, M.D.
Norton Cancer Institute

Sponsor: Lilly USA, LLC

Learn more at ClinicalTrials.gov

Email for more information: GU-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.